Coherus BioSciences Inc.

7.50+0.1100+1.49%Vol 1.68M1Y Perf -51.41%
Jun 24th, 2022 16:00 DELAYED
BID7.00 ASK7.60
Open7.48 Previous Close7.39
Pre-Market- After-Market7.50
 - -  - -%
Target Price
18.75 
Analyst Rating
Moderate Buy 2.00
Potential %
150.00 
Finscreener Ranking
★+     42.25
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
+     36.77
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
     39.28
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
13.85 
Earnings Rating
Strong Sell
Market Cap580.67M 
Earnings Date
4th Aug 2022
Alpha-0.02 Standard Deviation0.16
Beta1.21 

Today's Price Range

7.227.66

52W Range

5.6019.32

5 Year PE Ratio Range

-2.7019.20

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
19.05%
1 Month
1.21%
3 Months
-39.66%
6 Months
-57.82%
1 Year
-51.41%
3 Years
-64.52%
5 Years
-52.08%
10 Years
-

TickerPriceChg.Chg.%
CHRS7.500.11001.49
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
2.90
3.30
0.97
34.25
-7.00
Leverage Ratio 7.00
ProfitabilityValueIndustryS&P 500US Markets
80.40
-60.60
-59.50
-
-70.62
RevenueValueIndustryS&P 500US Markets
303.63M
3.92
63.96
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.80-1.24-55.00
Q04 2021-0.61-0.601.64
Q03 2021-0.40-0.49-22.50
Q02 2021-0.25-0.40-60.00
Q01 20210.09-2.37-2 733.33
Q04 20200.250.12-52.00
Q03 20200.350.33-5.71
Q02 20200.260.70169.23
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.98-100.00Negative
9/2022 QR-0.83-18.57Negative
12/2022 FY-3.77-46.69Negative
12/2023 FY-1.87-61.21Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.98
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.68M
Shares Outstanding77.42K
Shares Float61.14M
Trades Count10.06K
Dollar Volume12.60M
Avg. Volume1.25M
Avg. Weekly Volume1.62M
Avg. Monthly Volume1.13M
Avg. Quarterly Volume994.57K

Coherus BioSciences Inc. (NASDAQ: CHRS) stock closed at 7.5 per share at the end of the most recent trading day (a 1.49% change compared to the prior day closing price) with a volume of 1.68M shares and market capitalization of 580.67M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 317 people. Coherus BioSciences Inc. CEO is Dennis M. Lanfear.

The one-year performance of Coherus BioSciences Inc. stock is -51.41%, while year-to-date (YTD) performance is -53.01%. CHRS stock has a five-year performance of -52.08%. Its 52-week range is between 5.6 and 19.32, which gives CHRS stock a 52-week price range ratio of 13.85%

Coherus BioSciences Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of 41.41, a price-to-sale (PS) ratio of 1.58, a price to cashflow ratio of 20.10, a PEG ratio of 2.32, a ROA of -33.69%, a ROC of -37.23% and a ROE of -315.86%. The company’s profit margin is -70.62%, its EBITDA margin is -59.50%, and its revenue ttm is $303.63 Million , which makes it $3.92 revenue per share.

Of the last four earnings reports from Coherus BioSciences Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.98 for the next earnings report. Coherus BioSciences Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for Coherus BioSciences Inc. is Moderate Buy (2), with a target price of $18.75, which is +150.00% compared to the current price. The earnings rating for Coherus BioSciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Coherus BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Coherus BioSciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.29, ATR14 : 0.49, CCI20 : 52.89, Chaikin Money Flow : 0.21, MACD : -0.40, Money Flow Index : 56.39, ROC : -2.98, RSI : 52.17, STOCH (14,3) : 81.55, STOCH RSI : 1.00, UO : 62.47, Williams %R : -18.45), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Coherus BioSciences Inc. in the last 12-months were: James I. Healy (Sold 434 555 shares of value $7 250 063 ), McDavid Stilwell (Sold 3 507 shares of value $58 919 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (60.00 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (50.00 %)
2 (40.00 %)
2 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.00
Moderate Buy
1.80
Moderate Buy
1.67

Coherus BioSciences Inc.

Coherus BioSciences Inc is a United States based biotherapeutics company engaged in developing and commercializing biosimilar therapeutics. The company focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates. Geographically, the group has a business presence in the United States and other countries.

CEO: Dennis M. Lanfear

Telephone: +1 650 649-3530

Address: 333 Twin Dolphin Drive, Redwood City 94065, CA, US

Number of employees: 317

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

73%27%

Bearish Bullish

55%45%

News

Stocktwits